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Abstract
 
The studies performed to date analyzed the overall participation of the inducible costimulator
(ICOS) in model diseases, but did not yield information on the nature and function of ICOS-
expressing T cells in vivo. We examined ICOS
 
 
 
 T cells in the secondary lymphoid organs of
nonmanipulated mice, in the context of an “unbiased” immune system shaped by environmen-
tal antigens. Using single cell analysis, ICOS
 
low
 
 cells were found to be loosely associated with
the early cytokines interleukin (IL)-2, IL-3, IL-6, and interferon (IFN)-
 
 
 
. ICOS
 
medium
 
 cells, the
large majority of ICOS
 
 
 
 T cells in vivo, were very tightly associated with the synthesis of the T
 
helper type 2 (Th2) cytokines IL-4, IL-5, and IL-13, and these cells exhibited potent inflamma-
tory effects in vivo. In contrast, ICOS
 
high
 
 T cells were highly and selectively linked to the anti-
inflammatory cytokine IL-10. Overall, these data seem to indicate that ICOS cell surface den-
sity serves as a regulatory mechanism for the release of cytokines with different immunological
properties. Further in vivo functional experiments with in vitro–activated T cells strongly
suggested that the ICOS
 
 
 
 population, although representing in vivo only around 10% of T
cells bearing early or late activation markers, nevertheless encompasses virtually all effector T
cells, a finding with major diagnostic and therapeutic implications.
Key words: T helper cell • T lymphocyte subsets • Th2 cells • cytokine • inﬂammation
 
Introduction
 
Inducible costimulator (ICOS)
 
*
 
 is a T cell–specific cell sur-
face molecule structurally related to CD28 and CTLA-4 (1,
2). Early in vitro functional studies revealed that ICOS had
a costimulatory potential for the activation of T cells similar
to CD28 (1), but also revealed striking differences. In con-
trast to the constitutive expression of CD28, up-regulation
of ICOS requires prior activation of T cells (1, 2). Both co-
stimulatory molecules can amplify the secretion of a broad
spectrum of cytokines, but only CD28 coinduced substan-
tial amounts of IL-2, whereas ICOS showed a certain pref-
erence for the coinduction of IL-10 (1). Early in vitro and
in vivo experiments led to the paradigm that ICOS is pref-
erentially involved in Th2 immune responses (3, 4), but
subsequent work also demonstrated an essential contribu-
tion of ICOS to the pathogenesis of Th1-based murine
models (5–7) and thus challenged this paradigm. Mice with
a deleted ICOS gene revealed defects in the generation of
IL-4 and IL-13, but have an intact production of IL-10 on
stimulation in vitro (8). Thus, a number of studies suggested
that ICOS is linked to the secretion of certain cytokines,
but did not examine this important issue in detail.
Experiments performed to date on the function of ICOS
in vivo were typically performed using reagents blocking
the ICOS/ICOS-L interaction, and were designed to eval-
uate global parameters such as clinical scores, transplant sur-
vival rates, or cytokine levels in the body (3, 5, 6, 9–11).
This approach yielded important information on the over-
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magnetic cell sorting; pLN, peripheral LN; PP, Peyer’s patch.T
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all biological role of ICOS and its potential for therapeutic
intervention, but did not provide any direct information on
the nature of ICOS-bearing T cells in vivo. Therefore, the
exact function of ICOS
 
 
 
 T cells still remains ill defined.
In the presented work, we characterized for the first time
ICOS-expressing cells obtained directly ex vivo. We chose
to study the unmanipulated mouse in order to be able to
analyze ICOS
 
 
 
 cells in the context of an “unbiased” im-
mune system at steady state. We examined ICOS-express-
ing T cells from central lymphoid compartments, where
naive T cells encounter antigen and undergo a series of dif-
ferentiation steps before becoming effector cells. The stud-
ies were performed at the single cell level, yielding maxi-
mal information on the expression of cell surface antigens
and single cytokines. We observed for the first time an in-
triguing correlation between the expression levels of a cell
surface molecule and the type of cytokine produced, sug-
gesting a novel regulatory mechanism in vivo: in CD4
 
 
 
 T
cells, intermediate levels of ICOS were tightly correlated to
the synthesis of the proinflammatory Th2 cytokines IL-4,
IL-5, and IL-13, whereas high levels of ICOS were corre-
lated to the synthesis of the antiinflammatory cytokine IL-
10. In fact, CD4
 
 
 
 T cells expressing high levels of ICOS
predominantly secreted IL-10. Further cytokine expression
and functional studies demonstrated that ICOS is clearly
superior to the available early and late activation markers in
defining effector T cells.
 
Materials and Methods
 
Mice.
 
Mice transgenic for the OVA-specific DO11.10 T cell
receptor (OVA-TCR; reference 12) were from Dr. D. Loh,
Washington University School of Medicine, St. Louis, MO and
maintained on the BALB/c background. BALB/c mice were
bred under SPF conditions and kept under SPF conditions or un-
der conventional conditions at two different facilities. All animal
experiments were performed in accordance with institutional and
state guidelines.
 
Generation of ICOS-specific mAb.
 
Lewis rats were immunized
with a murine ICOS-rabbit-Ig fusion protein (13). Spleen cells
were fused with myeloma P3X63Ag8.653 (American Type Cul-
ture Collection) and the resulting hybridomas were screened by
flow cytometry using L-cells transfected with murine ICOS (13).
From 12 mAb obtained, MIC-280 (rat IgG2b) gave the brightest
staining in flow cytometry and was used in this study.
 
Phenotypic Analysis of Cells from Secondary Lymphoid Tissue.
 
Single cell suspensions from spleens, peripheral lymph nodes
(pLN; axillary, inguinal, popliteal, illeosacral, and cervicalis super-
ficialis), Peyer’s patches (PP), and appendix-associated lymphoid
follicles were prepared from normal, 6-mo-old BALB/c mice.
The cells were stained with digoxigenized anti-murine ICOS
mAb (MIC-280), FITC-labeled anti-CD4 mAb (GK1.5; Ameri-
can Type Culture Collection), and biotinylated mAb against acti-
vation markers CD69 (H1.2F3), CD25 (7D4), CD44 (IM7),
CD45RB (23G2; all from BD Biosciences), and CD62L (MEL-
14; American Type Culture Collection). To prevent unspecific
binding of mAb, all samples were preincubated with blocking
anti-Fc
 
 
 
RII/III mAb (2.4G2; 100 
 
 
 
g/ml; American Type Cul-
ture Collection) and purified rat IgG (200 
 
 
 
g/ml; Nordic) 10 min
before and during staining with the mAb. Cy5-conjugated anti-
 
digoxigenin (Dig) Fab (Roche Biochemicals) and streptavidin-PE
(BD Biosciences) were used as secondary reagents.
Specificity of staining with the digoxigenized anti-ICOS mAb
MIC-280 was controlled by preincubating cells with a 100-fold
excess of unconjugated MIC-280. Samples (
 
 
 
200,000 cells) were
analyzed on a FACSCalibur™ using CELLQuest™ software
(Becton Dickinson). Analysis gates were set on viable CD4
 
 
 
 T
cells, based on forward and side light scatter and exclusion of pro-
pidium iodide–positive cells (0.3 
 
 
 
g/ml; Sigma-Aldrich).
 
Magnetic Cell Sorting.
 
Single cell suspensions from pLN,
spleens, and PP of normal, 3–8-mo-old BALB/c mice or from in
vitro cultures of DO11.10 spleen cells were stained with digoxi-
genized anti-ICOS mAb MIC-280 for 10 min on ice, followed
by anti-Dig Fab conjugated to magnetic beads (Miltenyi Biotec)
for 15 min, and anti-Dig-Cy5 for additional 5 min at 10
 
 
 
C. To
prevent unspecific binding of the anti-ICOS mAb, the cells were
preincubated with blocking anti-Fc
 
 
 
RII/III mAb 2.4G2 (200
 
 
 
g/ml) and purified rat IgG (500 
 
 
 
g/ml) as described above.
Cells were washed and passed over a “mock” LS magnetic cell
sorting (MACS
 
®
 
) column (Miltenyi Biotec), which was not in-
serted into the magnetic field, to remove cells that bound non-
specifically to the column. ICOS
 
 
 
 cells were obtained by two
consecutive passes over LS columns inserted into a MidiMACS
 
®
 
magnet (Miltenyi Biotec). To stringently deplete ICOS
 
 
 
 cells
from the cells that passed through the column, the cells of the
first passage fraction were reapplied to a new LS column, to
which a 26-gauge needle was attached to restrict the flow rate,
thus removing also cells expressing ICOS only at a low level.
 
Flow Cytometric Analysis for Intracellular Cytokines.
 
Cells were
suspended at 10
 
6
 
/ml in complete RPMI 1640, supplemented
with 10% fetal calf serum, 0.3 mg/ml glutamine, 10 
 
 
 
M 2-mer-
captoethanol, 100 U/ml penicillin, and 0.1 mg/ml streptomycin
and stimulated with phorbol 12-myristate 13-acetate (PMA; 10
ng/ml) and ionomycin (1 
 
 
 
g/ml), with Brefeldin A (5 
 
 
 
g/ml; all
from Sigma-Aldrich) added at 2 h. After 4.5–5 h, the cells were
washed in PBS and fixed with 2% formaldehyde in PBS for 15
min at RT. Fixed cells were washed in PBS supplemented with
0.5% BSA and 0.02% sodium azide (PBS/BSA/azide), and
stained with biotinylated anti-CD4 mAb (GK1.5), followed by
streptavidin-PerCP (BD Biosciences). For intracellular cytokine
detection, cells were permeabilized with 0.5% saponin (Sigma-
Aldrich) in PBS/BSA/azide and stained with two of the follow-
ing rat anti–mouse cytokine mAb conjugated to PE or FITC for
15 min at RT: PE-coupled anti–IL-3 (8F8), anti–IL-4 (11B11),
anti–IL-6 (20F3), anti–IL-10 (JES5–16E3; all from BD Bio-
sciences), and anti–IL-13 (38213.11; R&D Systems), and FITC-
coupled anti–IFN-
 
 
 
 (AN18.17.24; ref. 14), anti–IL-2 (S4B6;
American Type Culture Collection), anti–IL-5 (TRFK5), anti–
TNF-
 
 
 
 (MP6-XT22), and anti–GM-CSF (22E9; all from BD
Biosciences). PE- or FITC-labeled isotype control mAb (BD
Biosciences) were used at the same concentrations as the respec-
tive anti-cytokine mAb. Unspecific binding of the mAb was
blocked by preincubating the fixed cells with blocking anti-
FcgRII/III mAb 2.4G2 (50 
 
 
 
g/ml) and purified rat IgG (200
 
 
 
g/ml) in 0.5% saponin in PBS/BSA/azide. After intracellular
cytokine staining, cells were washed twice in 0.5% saponin in
PBS/BSA/azide. Samples (
 
 
 
200,000 cells) were analyzed by
four-color flow cytometry on a FACSCalibur™.
 
Analysis of the Correlation Between ICOS Expression and Cytokine
Production.
 
Cells from pLN of normal BALB/c mice were
stained for ICOS, stimulated, and further stained for CD4 and in-
tracellular cytokines. ICOS surface expression (gated on CD4
 
 
 
cells) was plotted against the staining intensity of single intracellu-T
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lar cytokines. In this plot, adjacent analysis regions containing at
least 1,000 CD4
 
 
 
 cells with a distinct ICOS staining intensity
were defined. The percentage of cytokine-positive cells in each
analysis region was determined and plotted against the mean fluo-
rescence intensity of ICOS expression. To cope with the extreme
rareness of ICOS-bright cells in unseparated pLN cells obtained
directly ex vivo, data for cells with an ICOS fluorescence inten-
sity 
 
 
 
100 were obtained from ICOS-enriched CD4
 
 
 
 pLN cells
stimulated and stained in the same experiment.
 
Cytokine ELISA.
 
Supernatants from cell cultures stimulated
for 20–24 h with PMA and ionomycin were analyzed for differ-
ent cytokines by sandwich ELISA. For the quantitation of IL-2,
IFN-
 
 
 
, IL-4, IL-5, and IL-10 we used JES6–1A12, R4–6A2,
11B11, TRFK5, and SXC-1 as coating mAb and biotinylated
JES6–5H4, AN18.17.24, BVD6–24G2, TRFK4, and JES5–2A5
as detection mAb, respectively.
 
In Vitro Stimulation of OVA-specific T Cells.
 
Spleen cells from
DO11.10 mice, which had been magnetically depleted of CD8
 
 
 
cells, were stimulated with the peptide OVA
 
323–339
 
 (0.2 
 
 
 
M; syn-
thesized by Dr. P. Henklein, Charité, Berlin, Germany) at 2 
 
 
 
10
 
6
 
/ml in complete RPMI. Before magnetic sorting, dead cells
were removed by Ficoll-gradient centrifugation (Ficoll Histo-
paque
 
®
 
-1083; Sigma-Aldrich).
 
Design and Analysis of the Adoptive Transfer Animal Model.
 
Unseparated, ICOS-depleted, and ICOS-enriched fractions con-
taining identical numbers of CD4
 
 
 
KJ1–26
 
 
 
 T cells (1.5 
 
 
 
 10
 
6
 
/
mouse) were injected intravenously into the tail vein of recipient
BALB/c mice (6–8 animals per group, 4 animals in control
group). The recipient mice had been exposed to an aerosol (for
20 min) of 1% OVA (Sigma-Aldrich) in PBS or, as a control, PBS
without OVA 24 h before. 24 h and 48 h after cell transfer, the
recipients were again exposed to OVA or PBS nebulization. Mice
were killed on day 4. Lungs were washed via the trachea with 2
ml of PBS, and the cells analyzed by flow cytometry or centri-
fuged onto slides. Cells on slides were stained with Diff-Quick
 
®
 
(Dade AG) and differentiated by counting at least 200 cells. Lungs
were inflated through the trachea with 1.6 ml of 50% Tissue-Tek
(Miles Diagnostics) in PBS, and the right lower lobe was snap-
frozen in cold isopentane. Lung cryostat sections (8 
 
 
 
m) were
stained with mAb against CD3 (KT3; reference 15), CD45R/
B220 (RA3–6B2; reference 16), F4/80 (F4/80; American Type
Culture Collection), and Ly-6G (RB6–8C5; ref. 17), using the
APAAP technique (18), and analyzed by light microscopy. Major
basic protein (MBP; reference 19) was stained with a polyclonal
rabbit anti–mouse Ab (provided by Drs. G. Gleich and J. Lee,
Mayo Clinic, Scottsdale, AZ, and Rochester, MN; reference 20),
followed by anti–rabbit-Ig-FITC, and analyzed on a LSM-510 la-
ser scanning microscope (Carl Zeiss Microimaging, Inc.). Cells
obtained from peribronchial or inguinal lymph nodes or bron-
choalveolar lavage (BAL) were stained with a combination of
mAb directed to ICOS (MIC-280-PE), OVA-TCR (KJ1–26-
Dig, followed by anti-Dig-Cy5), CD62L (MEL-14-FITC), or
CD69 (H1.2F3-FITC).
 
Results
 
ICOS Is Expressed on a Subpopulation of Antigen-experi-
enced CD4
 
 
 
 T Cells In Vivo.
 
We generated mAb MIC-
280, an antibody with optimal flow cytometry staining
properties, and analyzed the expression of ICOS in vivo.
Around 2.5% of CD4
 
 
 
 T cells from pLN, 6% of CD4
 
 
 
 T
cells from PP, and 1.1% of splenic CD4
 
 
 
 T cells from non-
 
immunized mice expressed ICOS, but only a very small
fraction of CD8
 
 
 
 T cells (less than 0.3% in pLN). We
therefore focused our further analysis on CD4
 
 
 
 T cells. Us-
ing the expression density of CD44 and CD45RB as crite-
ria, 
 
 
 
95% of ICOS
 
 
 
 CD4
 
 
 
 cells in vivo were T cells with
previous antigen exposure (Fig. 1 A). However, ICOS was
expressed only on around 10% of CD4
 
 
 
 pLN cells pre-
viously exposed to antigen (CD44
 
high
 
, CD45RB
 
low
 
, or
CD62L
 
low
 
). More surprisingly, again only around 10% of T
cells bearing CD69 or CD25 in vivo, markers typically ex-
pressed on recently activated T cells, coexpressed ICOS
(Fig. 1 A). Similar data were obtained for PP and splenic
CD4
 
 
 
 T cells (unpublished data). Collectively, these results
suggested that ICOS expression in vivo characterizes a sub-
population of antigen-experienced T cells with a particular
biological role.
 
ICOS Expression on CD4
 
 
 
 T Cells In Vivo Is Highly Cor-
related with the Capacity to Secrete IL-13, IL-4, IL-5, and in
Particular IL-10.
 
To define the functional properties of
CD4
 
 
 
ICOS
 
 
 
 cells in vivo, we examined whether ICOS
expression is correlated with a specific cytokine pattern.
Upon stimulation with PMA and ionomycin in the pres-
ence of Brefeldin A, the majority of the unseparated
CD4
 
 
 
 pLN T cells (58.7%) generated TNF-
 
 
 
, as deter-
mined by single cell analysis (Fig. 1 B, left column, and
Table I). The frequency of unseparated pLN CD4
 
 
 
 T cells
capable of secreting IL-3, IL-6, IFN-
 
 
 
, IL-2, GM-CSF,
IL-13, IL-4, IL-5, or IL-10 was substantially lower and
was in the 0.1-4.8% range (Fig. 1 B, left column, and Ta-
ble I). Coexpression analysis of cytokines and ICOS deter-
mined that only around 9% of TNF-
 
 
 
–secreting cells, but
21-42% of cells secreting IL-3, IL-6, IFN-
 
 
 
, IL-2, or
GM-CSF, and even 46–58% of cells secreting IL-13, IL-4,
IL-5, or IL-10 expressed ICOS (Table I). These results
demonstrated that ICOS
 
 
 
 T cells, although representing
only a small fraction of antigen-experienced cells in nor-
mal mice, nevertheless encompass a large proportion of
cells capable of secreting effector cytokines, in particular
IL-13, IL-4, IL-5, and IL-10.
 
The Degree of ICOS Cell Surface Density on CD4
 
 
 
 T Cells
Is Directly Correlated with the Cytokine Pattern Secreted.
 
For an extended cytokine pattern analysis we magnetically
sorted ICOS
 
 
 
 T cells from pLN cells. This procedure re-
sulted in a pure population of ICOS
 
 
 
 T cells (“ICOS-
enriched”), with around 30% of cells expressing low amounts,
and 70% of CD4
 
 
 
 cells expressing intermediate to high
amount of ICOS on the cell surface (Fig. 1 C). The nega-
tive population (“ICOS-depleted,” Fig. 1 C) was strin-
gently depleted of ICOS-bearing cells by two rounds of
magnetic separation. In relation to the ICOS-depleted cell
population, enrichment for ICOS
 
 
 
 cells resulted in a rela-
tive reduction of TNF-
 
 
 
–generating cells and in a slight
enrichment of T cells secreting IL-3, IL-6, IFN-
 
 
 
, IL-2,
and GM-CSF (1.3 to 2.6-fold, Fig. 1 B, middle and right
column, and Table II). At the same time, a strong enrich-
ment for cells secreting IL-13, IL-4, and IL-5 (13-fold),
and a dramatic enrichment for cells generating IL-10 (28-
fold) were observed (Fig. 1 B and Table II), resulting ap-T
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Figure 1. Phenotype and cytokine pattern of ICOS-expressing CD4  T cells in vivo. (A) ICOS is expressed on a subpopulation of antigen-experi-
enced CD4  T cells in vivo. Cells from pLN of 6-mo-old BALB/c mice were stained with mAb against CD4, ICOS, and a panel of T cell activation
markers, as indicated. In each case, the specificity of ICOS staining was controlled by preincubating the cells with an excess of unconjugated anti-ICOS
mAb (cold blocking control, only shown for CD69 coexpression analysis). Analysis gates were set on live CD4  T lymphocytes. The inserted numbers
represent the net percentage of ICOS-positive and/or activation marker-positive CD4  cells after subtraction of the respective cold-blocking controls.
(B) ICOS expression on CD4  T cells in vivo correlates with a Th2-biased, IL-10–dominated cytokine pattern. Unseparated, ICOS-depleted, and
ICOS-enriched (compare panel C) pLN cells were stimulated with PMA and ionomycin for 5 h in the presence of Brefeldin A for the last 3 h. After fix-
ation, cells were stained for CD4, and simultaneously for the indicated intracellular cytokines. The inserted numbers represent percentages of CD4  cells
generating a given cytokine. The results shown are representative of three independent experiments. (C) Separation of ex vivo T cells into ICOS-
depleted and ICOS-enriched populations. Cells from pLN of BALB/c mice were stained with digoxigenized anti-ICOS mAb MIC-280, followed by
anti-Dig MACS microbeads and anti-Dig-Cy5. The cells were separated by MACS and stained also for CD4. Similar numbers of CD4  T cells of the
unsorted and sorted fractions are shown. Percentages of ICOS  cells in the CD4  population are indicated. The specificity of enrichment for ICOS 
cells is reflected by the selective accumulation of CD4  cells in the ICOS-enriched fraction.T
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parently from a preferential accumulation of ICOS “high
expressors” in the ICOS-enriched population. Similar data
were obtained with T cells recovered from PP and spleen
(unpublished data). The dramatic increase in IL-10  T cells
in the ICOS-enriched fraction was independent of
whether the IL-10 producer did or did not coexpress IL-2
(Fig. 1 B), IFN- , IL-4, or IL-5 (unpublished data).
The high enrichment of T cells secreting certain cyto-
kines in the ICOS  cell fraction suggested that the amount
of ICOS expressed on the cell surface might be directly
correlated to the type of cytokine secreted. To test this hy-
pothesis, we plotted the percentages of cells secreting a
given cytokine against the density of ICOS expressed on
the cell surface, measured as relative fluorescence intensity.
The result of this analysis is shown for each single cytokine
(Fig. 2 A), as well as cumulatively for all cytokines mea-
sured (Fig. 2 B). This analysis revealed that T cells negative
for ICOS almost exclusively secreted TNF-  and thus ex-
hibited a cytokine pattern typical of naive T cells (21). T
cells with low levels of ICOS showed a reduced TNF- 
secretion, significant IL-2 and IFN-  secretion, and the ca-
pacity to generate IL-3 and GM-CSF (Fig. 2, A and B). In-
termediate ICOS expression was associated with the pro-
duction of IL-5, IL-13, and IL-4. High levels of ICOS on
the cell surface were very strongly correlated with the gen-
eration of IL-10. In fact, in CD4  T cells with the highest
expression of ICOS, IL-10 was the dominant cytokine
produced (Fig. 2, A and B).
ICOS  T Cells Isolated Ex Vivo Exhibit a Stable Cytokine
Pattern. To determine whether the capacity to secrete
certain cytokines is a stable feature of cells expressing ICOS
in vivo, ICOS-depleted and ICOS-enriched CD4  T cells
Table I. Coexpression Analysis of Cytokines and ICOS in CD4  T Cells
pLN CD4  T cells ex vivo TNF-  IL-3 IL-6 IFN-  IL-2 GM-CSF IL-13 IL-4 IL-5 IL-10
Total frequency of cells secreting a
given cytokinea
58.7% 1.0% 0.13% 4.8% 3.8% 0.9% 1.5% 1.2% 0.35% 0.7%
Proportion of ICOS  cells in the population
of CD4  T cells secreting a given cytokinea
9% 22% 21% 29% 23% 42% 56% 57% 58% 46%
apLN cells were activated with PMA and ionomycin for 5 h in the presence of Brefeldin A for the last 3 h and analyzed for intracellular cytokines by
flow cytometry.
Table II. Intracellular Cytokine Profiles of Sorted ICOS  and ICOS CD4  T Cells
pLN CD4  T cells ex vivo, freshly isolated TNF-  IL-3 IL-6 IFN-  IL-2 GM-CSF IL-13 IL-4 IL-5 IL-10
ICOS-depleted
Frequency of cells secreting a given cytokinea 79.5% 1.1% 0.12% 5.8% 4.2% 0.7% 0.7% 0.6% 0.14% 0.4%
ICOS-enriched
Frequency of cells secreting a given cytokinea 45.1% 1.4% 0.22% 13% 10% 1.8% 8.6% 8% 1.9% 11.3%
Factor of increaseb 0.6  1.3  1.8  2.2  2.4  2.6  12.3  13.3  13.6  28.3 
pLN CD4  T cells ex vivo,
cultured for 6 d in vitroc
ICOS-depleted
Frequency of cells secreting a given cytokinea 84.1% 0.3% n.d. 12.5% 7.2% n.d. 0.21% 0.5% 0.01% 0.2%
ICOS-enriched
Frequency of cells secreting a given cytokinea 56.2% 0.5% n.d. 18.4% 12.5% n.d. 6.7% 9.6% 0.56% 14.9%
Factor of increaseb 0.7  1.7  n.d. 1.5  1.7  n.d. 31.9  19.2  56  74.5 
n.d., not determined.
apLN cells were activated with PMA and ionomycin for 5 h in the presence of Brefeldin A for the last 3 h and analyzed for intracellular cytokines by
flow cytometry.
bObtained when comparing ICOS-depleted to ICOS-enriched cell populations.
cpLN cells were magnetically sorted into ICOS-depleted and ICOS-enriched cell fractions, stimulated with PMA and ionomycin for 36 h, trans-
ferred into fresh medium, and further cultured for 6 d. At the end of culture, CD4  T cells were restimulated and analyzed for intracellular cytokines
as above.T
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were activated, cultured in vitro for 6 d, and reexamined
for their cytokine generation. Remarkably, after this cul-
ture period the cytokine patterns of T cells in the ICOS-
depleted and ICOS-enriched fractions closely resembled
the cytokine patterns of ICOS-depleted and ICOS-
enriched T cells directly obtained ex vivo, before culture
(Table II). In particular, virtually all T cells secreting IL-13,
IL-4, IL-5, and IL-10 were found in the ICOS  fraction
on day 6 of culture. These experiments clearly demon-
strated that ICOS  T cells exhibit a memory for the cyto-
kines generated, at least in the short term.
In Vitro–activated Splenic CD4  Cells from DO11.10 Mice
with Stable ICOS Expression Preferentially Secrete IL-4, IL-13,
IL-5, and IL-10. As ICOS  T cells are capable of synthe-
sizing a variety of cytokines with partly opposing biological
roles (e.g., IFN-  and IL-4), we were interested to test the
overall biological effects of ICOS-expressing CD4  T cells
in vivo using an adoptive transfer model. To this end, we
chose an airway inflammation model which allows a func-
tional testing of both Th1- and Th2-biased immune re-
sponses (neutrophilic versus eosinophilic lung inflamma-
tion). However, one limitation for this type of experiment
Figure 2. The degree of ICOS cell sur-
face expression on CD4  T cells is corre-
lated with the cytokine pattern secreted.
Cells from pLN of BALB/c mice were
stained for ICOS and sorted according to
ICOS expression. Unseparated or ICOS-
enriched cells were activated with PMA and
ionomycin for 5 h in the presence of Brefel-
din A for the last 3 h, stained for CD4 and
various intracellular cytokines, and analyzed
by flow cytometry. ICOS surface expression
on CD4  T cells, measured as relative fluo-
rescence intensity, was correlated to the
percentage of cells capable of secreting a
given cytokine. The percentage of CD4  T
cells secreting the indicated cytokines is
plotted in correlation to their ICOS cell
surface expression density (A). Peak and
mean ICOS fluorescence intensities of
CD4  T cells secreting a given cytokine are
indicated. Note the different scale for
TNF- . The same data are plotted for all
cytokines in a cumulative fashion in B.T
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was the low total number of ICOS CD4  T cells which
could be isolated from pLN of TCR-transgenic mice. We
therefore undertook in vitro studies to identify conditions
for the isolation of preactivated ICOS-expressing cells with
the characteristic cytokine profile observed in vivo. When
DO11.10 CD4  T cells were activated with OVA323–339,
we noticed that virtually all CD4  T cells expressed ICOS
on day 3, but only a fraction of cells maintained ICOS sur-
face expression at a high level beyond day 5 (Fig. 3 A).
When the cultured cells were separated on day 6 into
ICOS  and ICOS  fractions (Fig. 3 B) and restimulated,
the vast majority of cells from the ICOS  fraction contin-
ued to express ICOS at high levels and thus exhibited
memory for the expression of ICOS. In contrast, only a
minority of cells from the ICOS-depleted fraction tran-
siently expressed ICOS (Fig. 3 C, top panel). On the other
hand, both populations up-regulated and down-regulated
CD69 in a similar fashion (Fig. 3 C, bottom panel). The
ICOS  T cell fraction, when compared with the ICOS 
cell fraction, exhibited a slightly reduced capacity to pro-
duce TNF-  and IL-3, a modestly increased capacity to
produce IFN- , IL-2, and GM-CSF, and a substantially
increased capacity to generate IL-4, IL-13, IL-5, and in
particular IL-10 (Fig. 4 A), and thus exhibited a cytokine
pattern similar to T cells expressing ICOS in vivo. These
data on cytokine secretion were also confirmed by ELISA
(Fig. 4 B). Additional experiments revealed that this cyto-
kine pattern remained stable in vitro for at least further 7 d
(unpublished data).
The ICOS  T Cell Fraction Contains Virtually All Inflam-
matory Effector Cells. In a next step we assessed the overall
biological effect of ICOS  T cells in vivo. CD4  T cells
from DO11.10 mice were cultured in the presence of
OVA323–339 for 6 d in vitro and magnetically separated into
ICOS  and ICOS  cell fractions, as before (compare Fig.
3 B). ICOS , ICOS , and unseparated cell fractions con-
taining equal numbers of OVA-TCR transgenic KJ1–26 
cells (22) were transferred into BALB/c recipients, which
had been exposed to OVA via the airways 24 h before
(Fig. 5 A). Recipient mice were then reexposed to OVA
Figure 3. Generation of OVA-specific CD4  T cells with stable ICOS expression in
vitro. (A) Prolonged ICOS expression on a subset of antigen-stimulated CD4  T cells in
vitro. CD8-depleted DO11.10 spleen cells were stimulated with OVA323–339, and ali-
quots stained daily for CD4, the OVA-TCR (mAb KJ1–26), and ICOS. The specificity
of ICOS staining (black line) was established using a cold blocking control (gray line).
Analysis gates were set on live CD4 OVA-TCR  lymphocytes. Results shown are rep-
resentative of four independent experiments. (B) Separation of OVA-specific, in vitro–
activated CD4  T cells into ICOS  and ICOS  populations. The cells stimulated as in
panel A were on day 6 magnetically separated into ICOS  and ICOS  fractions and
stained for CD4, CD69, and ICOS. Analysis gates were set on live CD4  lymphocytes.
The inserted numbers represent the percentages of CD4  cells in each quadrant. (C) Sta-
ble ICOS expression on sorted ICOS CD4  T cells. Unseparated (squares), ICOS-
depleted (triangles), and ICOS-enriched (circles) CD4  OVA-specific T cells obtained
on day 6 of culture with OVA323–339 were restimulated with PMA and ionomycin for
22 h, transferred into fresh medium, and further cultured for a total of 5 d. Immediately
after separation into fractions, and then in daily intervals, aliquots of the cell populations
were stained for CD4, CD69, and ICOS. In each case, the specificity of the ICOS staining was established using a cold blocking control. Analysis gates
were set on live CD4  lymphocytes. Percentages of ICOS  and CD69  cells in the CD4  populations are indicated. Similar results were obtained in
two independent experiments.T
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on days 1 and 2 after transfer, killed on day 4, and ana-
lyzed. In all three groups of mice we found a local accu-
mulation of OVA-TCR  T cells in peribronchial LN
(1.2–3.6% of T cells; Fig. 5 B) and BAL fluid (4.5–6.2%),
but not inguinal LN (0.2–0.4%), demonstrating a success-
ful homing of OVA-specific T cells to the site of antigen
delivery. In agreement with our findings of stable ICOS
expression in vitro (see Fig. 3 C, top panel), only in recip-
ients of ICOS  cells a significant proportion of OVA-
TCR  cells in peribronchial LN and BAL fluid expressed
ICOS on the cell surface (Fig. 5 B and Table III). In con-
trast, similar frequencies of CD69  and CD62Llow cells in
the OVA-TCR  populations were found in all three
groups of mice that were exposed to OVA (Table III), but
not in the PBS control mice (unpublished data). This indi-
cates that in all transferred animal groups a substantial pro-
Figure 4. In vitro–generated ICOS  T cells have a similar Th2-biased,
IL-10–dominated cytokine pattern as ICOS  T cells ex vivo. (A) Unsepa-
rated, ICOS-depleted, and ICOS-enriched cells obtained on day 6 of cul-
ture with OVA323–339 were stimulated with PMA and ionomycin for 4.5 h
in the presence of Brefeldin A for the last 2.5 h. After fixation, cells were
stained for the OVA-TCR with mAb KJ1–26 and for various intracellular
cytokines. Analysis gates were set on OVA-TCR  lymphocytes. Percent-
ages of cytokine-positive cells in the OVA-TCR  population are indicated.
Similar results were obtained in three independent experiments. (B) The
same T cell populations were stimulated with PMA and ionomycin for 20 h.
Cytokine concentrations in the supernatants were determined by ELISA.
Similar results were obtained in three independent experiments.T
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Figure 5. Only the ICOS  but not the ICOS  CD4 T cells are inflammatory
effectors. (A) Experimental design. CD8-depleted DO11.10 spleen cells were
stimulated with OVA323–339. On day 6, the cells were separated into ICOS  and
ICOS  fractions as shown in Fig. 3 B. Unseparated, ICOS-depleted, and ICOS-
enriched fractions containing identical numbers of CD4 OVA-TCR  T cells
(1.5   106/mouse) were transferred intravenously into BALB/c recipients ex-
posed to an aerosol of OVA in PBS 24 h earlier. On days 1 and 2 after the trans-
fer, the recipients were again exposed to OVA nebulization. On day 4, BAL was
performed, and lung tissue, peribronchial and inguinal LN cells were removed and
analyzed. (B) Stable ICOS expression in vivo. On day 4 after transfer, peribronchial LN cells from the three experimental groups were stained for ICOS,
OVA-TCR, and CD3. Analysis gates were set on CD3  T cells. The inserted numbers represent the percentages of CD3  cells in each quadrant. Note
that the vast majority of transgenic T cells in the ICOS-enriched recipients express ICOS, albeit to varying degree. (C) Accumulation of inflammatory
effector cells in the airway lumen is strictly dependent on the presence of ICOS  T cells. On day 4 after cell transfer, the total number and frequency of
lymphocytes, macrophages, neutrophils, and eosinophils in the BAL fluid were determined. The mice of the control group had been transferred with un-
separated CD4 OVA-TCR  T cells but had been exposed to PBS instead of OVA aerosol. Data are shown as the mean   SEM of 6–8 animals. Similar
results were obtained in two independent experiments. (D) Peribronchial infiltration of inflammatory effector cells in the lung is highly dependent on the
presence of ICOS  T cells. Lung sections of animals transferred with ICOS  and ICOS  cell fractions were stained for T cells (CD3), B cells (CD45R/
B220), macrophages (F4/80), neutrophils (Ly-6G), and eosinophils (major basic protein, MBP), and analyzed by conventional and confocal laser micros-
copy (original magnification 20 , bar scale indicates 50  m; AS, alveolar space; BL, bronchial lumen; EP, epithelium).T
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portion of OVA-specific T cells became activated by the
antigen in vivo.
We also tested whether the cytokine pattern of the trans-
ferred cells remained stable in vivo. For this, we activated
peribronchial LN cells from recipient mice and analyzed
the cytokine production of OVA-TCR  T cells (Table
IV). The differences in the cytokine profiles between trans-
ferred ICOS-depleted and ICOS-enriched T cells were
comparable to the results obtained before transfer.
We next analyzed the three groups of recipient mice for
signs of airway inflammation. In mice transferred with the
ICOS  cell fraction, the total numbers of lymphocytes,
macrophages, neutrophils, and eosinophils in the BAL fluid
increased dramatically (Fig. 5 C). The relative proportion
of lymphocytes, neutrophils, and eosinophils also increased,
and was accompanied by a relative decline of macrophages,
the most abundant cell population in the BAL (Fig. 5 C).
In stark contrast, the ICOS  cell fraction did not elicit any
measurable biological effects, when compared with control
animals transferred with the unseparated cells and exposed
to PBS instead of OVA (Fig. 5 C). Finally, we determined
the distribution of the infiltrating cells in the lungs by im-
munohistology. This analysis revealed high numbers of in-
filtrating T cells, B cells, macrophages, neutrophils, and
eosinophils in the peribronchial and perivascular regions of
small airways in animals transferred with ICOS  cells (Fig.
5 D), and thus resembled the pattern observed in murine
and human asthma (23, 24). In animals which had received
the unseparated cell fraction there were only low numbers
of infiltrating cells, but with a similar pattern (unpublished
data). In animals transferred with ICOS  cells, no infiltrates
were found with the exception of a modest number of
neutrophils in the peribronchial tissue (Fig. 5 D). Collec-
tively, the transfer experiments clearly demonstrated that
within the population of antigen-specific CD4  T cells vir-
tually all biological effects were exerted by cells bearing
ICOS on the cell surface.
Discussion
Our study reveals that expression of ICOS is an integral
part of a T cell differentiation program leading to the syn-
thesis of various effector cytokines, whereas ICOS  T
cells, typical of naive T cells (21), predominantly produce
the early inflammatory mediator TNF- . This general ob-
servation is not unexpected, given the fact that ICOS is
only significantly expressed on the surface after T cell acti-
vation (1, 2). A more detailed analysis, however, reveals a
number of intriguing findings. First of all, there is a clear
link between ICOS cell surface density and the type of
cytokines produced. A low expression of ICOS was associ-
ated with the generation of IL-2, IL-3, IL-6, and GM-
CSF, effector cytokines used in the early phase of an im-
mune response (25–29). At the same time, ICOS  T cells
represented only 20–30% (GM-CSF: 40%) of T cells capa-
ble of generating these early cytokines in vivo. Thus, at
least in an immune system at steady state, ICOS expression
is only loosely associated with early effector cytokines. In
contrast, intermediate expression of ICOS was found to be
tightly linked to the production of IL-4, IL-5, and IL-13
(Fig. 2). Here, ICOS  cells represented around 50% of all
T cells capable of producing these cytokines in lymphatic
Table III. Expression of Activation Markers on Adoptively 
Transferred T Cells in Lung Compartments of Recipient Mice
ICOS  CD69  CD62Llow
Peribronchial LN
Unseparated 7.4% 38.1% 81.1%
ICOS-depleted 1.2% 43.9% 78.4%
ICOS-enriched 37.9% 27.3% 77.2%
BAL
Unseparated 4.8%
ICOS-depleted 1.1%
ICOS-enriched 27.2%
Mice were adoptively transferred with T cell fractions as shown in Fig.
5 A. On day 4 of transfer, peribronchial LN cells and cells from the BAL
fluid were prepared and stained with mAb against CD3, the clonotypic
OVA-TCR (KJ1-26), ICOS, CD69, and CD62L. Percentages of
ICOS , CD69 , and CD62Llow cells in the CD3 OVA-TCR 
populations are given.
Table IV. Stability of Intracellular Cytokine Profiles of OVA-TCR  T Cells from Peribronchial LN after Adoptive Transfer
OVA-TCR  T cells ex vivo TNF-  IFN-  IL-2 IL-13 IL-4 IL-10
ICOS-depleted
Frequency of cells secreting a given cytokinea 46.6% 37.7% 21.4% 0.44% 3.3% 0.07%
ICOS-enriched
Frequency of cells secreting a given cytokinea 40.3% 42.6% 29.5% 1.9% 15.2% 4.2%
Factor of increaseb 0.9  1.1  1.4  4.3  4.6  60 
aMice were adoptively transferred with T cell fractions as shown in Fig. 5 A. On day 4 of transfer, peribronchial LN cells were prepared. Cells were
activated with PMA and ionomycin for 5 h in the presence of Brefeldin A for the last 3 h and analyzed for intracellular cytokines by flow cytometry.
Percentages of cytokine-producing cells in the CD4 OVA-TCR  populations are given.
bObtained when comparing ICOS-depleted to ICOS-enriched cell populations.T
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organs (Table I). These observations are highly significant,
as only very few percent of CD4  T cells in an immune
system at steady state express ICOS. Functionally, the link
to Th2 cytokines was demonstrated by induction of a mas-
sive Th2-type eosinophilic lung inflammation upon adop-
tive transfer of intermediate-to-high ICOS  T cells. Thus,
we can demonstrate a Th2 bias for the bulk of ICOS  T
cells in vivo. We interpret our findings as a basic functional
link between ICOS and effector cytokines, with a prefer-
ence for the Th2 cytokines IL-4, IL-5, and IL-13, but do
not exclude that under strong Th1-polarizing conditions,
this basic link can be temporarily overruled in favor of Th1
cytokines (5–7).
ICOS, however, is not only associated with the proto-
typical Th2 cytokines. An even stronger association could
be observed between ICOS and IL-10. First of all, around
50% of all T cells capable of generating IL-10 in vivo ex-
pressed ICOS (Table I). Second, and in a quite unique
fashion, IL-10 was the dominant cytokine produced by T
cells with high ICOS expression (Fig. 2). We thus demon-
strate for the first time a tight link between ICOS and IL-
10 in central lymphoid organs, and this statement also holds
true for the human immune system (unpublished data). In
fact, ICOS is the first surface molecule which can be corre-
lated to this central immune regulator (30). The observa-
tion that CD4  T cells from mice with a deleted ICOS
gene are fully capable of secreting IL-10 on CD3 stimula-
tion in vitro (8) seems to indicate that ICOS is not directly
involved in the differentiation of T cells to IL-10–secreting
cells, but rather controls the release of this cytokine.
The linkage between low ICOS expression and “early”
cytokines, and between intermediate/high ICOS expres-
sion and “late” cytokines is intriguing and could mean that
ICOS is gradually up-regulated in the course of progress-
ing T cell differentiation. First, T cells would utilize ICOS
for the release of proinflammatory Th2 cytokines, later a
population of T cells would differentiate to produce IL-10
and would utilize the high ICOS expression for an effec-
tive down-regulation of the immune response. In an al-
ternative scenario, T cells ICOSmedium/Th2 and T cells
ICOShigh/IL-10 would develop in parallel and then mi-
grate as effector cells to the periphery. Many peripheral tis-
sues, among them endothelial cells (ECs), constitutively
express low levels of ICOS-L in the resting state (31). Our
recent results indicate that upon inflammation, endothelial
cells strongly up-regulate ICOS-L (31). Under these con-
ditions, ligation of ICOS-L by ICOS is the main pathway
for the release of cytokines by CD4  T cells interacting
with ECs (31) presumed to present antigen (32, 33), as the
inflamed ECs remain negative for CD80 and CD86 (31–
33). ECs expressing low levels of ICOS-L can be pre-
sumed to preferentially trigger ICOShigh T cells releasing
predominantly IL-10, which has downmodulatory effects
on the production of cytokines by inflamed ECs (34, 35).
In contrast, ECs with higher levels of ICOS-L could also
activate the majority of T cells expressing lower levels of
ICOS and thus trigger the release of IL-4, IL-5, and IL-13,
which have proinflammatory actions on ECs (34, 36–39).
Regulated by a threshold expression of ICOS-L, this sce-
nario would result in an antigen-specific, localized opening
up of the endothelial barrier for the influx of inflammatory
cells into tissues. In fact, we have preliminary evidence that
such a mechanism is operative in vivo. In an abstract sense,
the quantitative differences in ICOS expression on CD4 
T cells would translate into qualitatively different biologi-
cal effects, depending on the level of ICOS-L expression
on the partner cell.
It seems that ICOS expression not only defines certain
cytokine patterns but altogether demarcates effector CD4 
T cells in vivo. Our data with stimulated DO11.10 spleen
cells clearly demonstrated that only CD4  T cells with pro-
longed expression of ICOS exhibit memory for the reex-
pression of ICOS. Based on their cytokine profile, it is very
probable that these cells were reactivated CD4  T cells
with previous antigen exposure and a history of differentia-
tion to effector cells in vivo. In line with this interpretation
were the dramatic biological effects exerted by these T cells
upon transfer into syngeneic hosts. Even more impressive,
however, was the observation that in our studies the T cell
fraction depleted of ICOS  T cells did not exert any mea-
surable biological effects upon adoptive transfer. Of note,
this ICOS  cell fraction was derived from an in vitro cul-
ture, in which virtually all T cells were fully activated and
expressed high levels of ICOS a few days before separation
into fractions (see Fig. 3 A). This ICOS  cell population
was fully capable of synthesizing TNF-  and IL-2 on re-
stimulation in vitro (Fig. 4) and exhibited high levels of
CD69 in the lung-draining peribronchial LN as a sign of
activation after exposure to OVA, their nominal antigen
(Table III). Nevertheless, no influx of cells into the lung or
any other sign of inflammation was induced by this ICOS 
T cell population.
Collectively, these data strongly suggest an association
between stable ICOS expression and T cell effector capac-
ity. This conclusion is corroborated by our initial finding
that only some 10% of CD4  T cells expressing in vivo
early (CD69 or CD25) or late (CD44high, CD45RBlow, or
CD62Llow) activation markers coexpress ICOS, but never-
theless represent the bulk of the T cell population capable
of secreting late effector cytokines (Fig. 1 and Table I).
Thus, ICOS seems to be a highly specific marker for effec-
tor T cells in vivo, an observation with high diagnostic and
therapeutic potential.
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